shan xi xi yue pharmaceutical company

Company Profile

Country: China (Mainland)

Business Type: Manufacturers

Mr.Carlifor wu
Tel: 86-913-4359600 86-574-27717055

Mobile:13957822021
Tel:86-913-4359600 86-574-27717055
Fax:
Province/state:Shan xi Province
City:Xi an
Street:Pharmacy Industry District , Jian She Road, Hua Yin ,Xi an China
MaxCard:

About us

Welcome To Our Site!
Shaanxi Xiyue Pharmaceutical Co., Ltd

Shaanxi Xiyue Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise integrating R & D, production and sales. Founded in 1992, it is a Sino Hong Kong joint venture jointly established by the former northwest No.2 synthetic pharmaceutical factory and Hong Kong Tianma trading company. It was acquired by haichenyun and all capital in November 2008 and transformed into a modern private enterprise with a registered capital of 50 million. It is located in the scenic area At the foot of Huashan Mountain, Longhai Railway in the south, Lianhuo Expressway in the north, about 120 kilometers away from the ancient city of Xi'an, with superior geographical location and convenient transportation.

The company has 105 products, 90 solid preparations (including 5 penicillin preparations) and 15 APIs. More than ten production lines of solid preparations (tablets, capsules, granules), penicillin preparations (capsules, granules) and APIs have passed GMP certification.

Annual production capacity: 1.2 billion tablets / granule / bag, more than 500 tons of API.

Shaanxi Xiyue Pharmaceutical (Fufeng) Co., Ltd

Shaanxi Xiyue Pharmaceutical (Fufeng) Co., Ltd. is a modern pharmaceutical enterprise integrating R & D, production and sales. It was founded in November 2017. It is a modern pharmaceutical manufacturer reconstructed by Shaanxi haichenyunhe Pharmaceutical Technology Co., Ltd. on the basis of acquisition of some assets of Shaanxi Yongshou Pharmaceutical Co., Ltd. It is located in Fufeng jiangzhang science and Technology Industrial Park, Baoji City, with registered capital of the company This is 68 million yuan, covering an area of 180 mu.

The main business scope of the company is the production and sales of APIs, capsules, granules, tablets, pharmaceutical intermediates, traditional Chinese medicine and medical devices; the research and development of new drugs, technology transfer and services. It has 16 products (gyzz), including 8 APIs, 8 preparations, and more than 10 new drugs of three or four categories under development and approval.

The project is constructed in two phases: the first phase covers an area of 100 mu, with a total planned investment of 550 million yuan and a construction area of more than 50000 square meters. It is planned to be completed and put into operation in 2020, with an annual output value of more than 1 billion yuan and profits and taxes of 200 million yuan. The second phase of the project covers an area of 80 mu, which is reserved for the construction of traditional Chinese medicine products and new drugs under research and approval.